Compare MNSB & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNSB | ALEC |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.1M | 167.6M |
| IPO Year | 2017 | 2019 |
| Metric | MNSB | ALEC |
|---|---|---|
| Price | $24.39 | $2.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.83 |
| AVG Volume (30 Days) | 29.7K | ★ 968.2K |
| Earning Date | 04-20-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | ★ 210.00 | N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $135,615,000.00 | $21,045,000.00 |
| Revenue This Year | $1.50 | $2.03 |
| Revenue Next Year | $3.77 | $29.87 |
| P/E Ratio | $23.32 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.86 | $1.09 |
| 52 Week High | $25.29 | $3.40 |
| Indicator | MNSB | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 58.89 | 65.56 |
| Support Level | $23.58 | $1.93 |
| Resistance Level | $25.16 | $2.10 |
| Average True Range (ATR) | 0.53 | 0.18 |
| MACD | 0.11 | 0.06 |
| Stochastic Oscillator | 94.65 | 81.60 |
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.